PMID- 15898294
OWN - NLM
STAT- MEDLINE
DCOM- 20050722
LR  - 20151119
IS  - 1545-9616 (Print)
IS  - 1545-9616 (Linking)
VI  - 4
IP  - 3
DP  - 2005 May-Jun
TI  - The successful use of etanercept in combination therapy for treatment of 
      acrodermatitis continua of hallopeau.
PG  - 360-4
AB  - Acrodermatitis continua of Hallopeau (ACH) is a rare form of pustular psoriasis 
      which poses a challenge to treat and causes considerable pain and suffering for 
      those afflicted. Tumor necrosis factor-alpha (TNF-alpha) is a pro-inflammatory 
      cytokine involved in the pathogenesis of ACH and other forms of psoriasis. 
      Inhibition of TNF-alpha has been shown to provide benefit in such inflammatory 
      conditions as rheumatoid arthritis, psoriatic arthritis, and, most recently, 
      plaque psoriasis. In this report, we present the case of a 65-year-old man with a 
      9-year history of recalcitrant ACH who demonstrated significant and sustained 
      clinical improvement when etanercept, a competitive inhibitor of TNF-alpha, was 
      added to his treatment regimen of acitretin and topical corticosteroids over a 
      12-week period.
FAU - Kazinski, Kimberly
AU  - Kazinski K
AD  - Department of Dermatology, San Antonio Uniformed Services Health Education 
      Consortium, Wilford Hall USAF Medical Center, San Antonio, TX, USA.
FAU - Joyce, Kathleen M
AU  - Joyce KM
FAU - Hodson, Darryl
AU  - Hodson D
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Drugs Dermatol
JT  - Journal of drugs in dermatology : JDD
JID - 101160020
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - LCH760E9T7 (Acitretin)
RN  - OP401G7OJC (Etanercept)
SB  - IM
CIN - J Drugs Dermatol. 2006 Sep;5(8):705-6. PMID: 16991229
MH  - Acitretin/*administration & dosage
MH  - Acrodermatitis/*drug therapy/pathology
MH  - Adrenal Cortex Hormones/*administration & dosage
MH  - Aged
MH  - Drug Therapy, Combination
MH  - Etanercept
MH  - Humans
MH  - Immunoglobulin G/*administration & dosage
MH  - Male
MH  - Psoriasis/drug therapy/pathology
MH  - Receptors, Tumor Necrosis Factor/*administration & dosage
EDAT- 2005/05/19 09:00
MHDA- 2005/07/23 09:00
CRDT- 2005/05/19 09:00
PHST- 2005/05/19 09:00 [pubmed]
PHST- 2005/07/23 09:00 [medline]
PHST- 2005/05/19 09:00 [entrez]
PST - ppublish
SO  - J Drugs Dermatol. 2005 May-Jun;4(3):360-4.